Related Experiment Videos
The UK Hib vaccine experience
1Department of Child Health and St George's Vaccine Institute, St George's Hospital Medical School, London, UK. pheath@sghms.ac.uk
Archives of Disease in Childhood
|May 23, 2002
Summary
The UK's Haemophilus influenzae type b (Hib) vaccine program, introduced in 1992, has nearly eliminated Hib disease in children. Ongoing surveillance remains crucial due to continued cases and evolving vaccination strategies.
Area of Science:
- Pediatric Infectious Diseases
- Vaccinology
- Public Health Microbiology
Background:
- Haemophilus influenzae type b (Hib) is a significant pathogen in young children.
- Hib conjugate vaccines were pioneers in routine childhood immunization schedules.
- The UK introduced a unique Hib vaccination program in 1992.
Purpose of the Study:
- To evaluate the impact and effectiveness of the UK's Hib conjugate vaccine program.
- To assess vaccine effectiveness, herd immunity, and risk factors for Hib disease.
- To monitor immunogenicity, immunological memory, and carriage of Hib post-vaccination.
Main Methods:
- Active national surveillance of Haemophilus influenzae disease.
- Analysis of vaccine effectiveness and herd immunity.
- Studies on immunogenicity, immune memory, and pharyngeal carriage.
Main Results:
- Near elimination of Hib disease in children under 5 years.
- Demonstrated high vaccine effectiveness and significant herd immunity.
- Identified risk factors for vaccine failure and non-b Hib invasive disease.
Conclusions:
- The UK Hib vaccine program has been highly successful in reducing disease incidence.
- Continued surveillance is essential due to persistent cases and introduction of new vaccines.
- Complacency regarding Hib disease prevention is not advised.